Granisetron Kabi

Granisetron Kabi is a prescription injectable solution that contains the active ingredient granisetron hydrochloride; the specific strength is not disclosed in the product listing. It belongs to the 5‑HT3 receptor antagonist class and is administered intravenously to help manage nausea and vomiting associated with certain medical procedures. It is marketed in the European Union and is used under medical supervision for antiemetic therapy in adult patients.

Granisetron Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic cancer treatments. - Prevention of postoperative nausea and vomiting (PONV) following surgical procedures that require general anesthesia. - Adjunct therapy for radiation‑induced nausea when used in combination with other antiemetics. - Use in patients who have not responded adequately to other 5‑HT3 antagonists.

The safety profile of Granisetron Kabi includes both common and less frequent adverse reactions.

Common: - Headache - Constipation - Diarrhea - Fatigue - Dizziness - Injection site pain - Dry mouth

Serious: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmia - QT interval prolongation - Severe hypotension

Before using Granisetron Kabi, clinicians should consider several precautionary factors to ensure safe administration.

- Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists. - Use caution in patients with known cardiac conduction disorders or prolonged QT interval. - Evaluate electrolyte balance, especially potassium, magnesium, and calcium levels, as abnormalities may increase cardiac risk. - Consider dose adjustment or monitoring in patients with hepatic impairment. - Avoid use in pregnant women unless the potential benefit justifies the risk, as safety data are limited. - Monitor for signs of serotonin syndrome when combined with serotonergic agents.

Granisetron Kabi may interact with other medications; awareness of these interactions helps prevent adverse effects.

Avoid: - Concurrent use with other 5‑HT3 receptor antagonists, which can increase the risk of cardiac toxicity. - Co‑administration with drugs known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics).

Use with caution: - Serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs) or tramadol, due to potential serotonin syndrome. - Anticholinergic medications that may exacerbate constipation. - CYP3A4 inhibitors or inducers, which could affect granisetron metabolism.